Just before the close of business last Friday, Mylan N.V. announced it would pay $465 million to the U.S. Justice Department and other agencies to resolve regulatory questions about the company’s alleged misclassification of the EpiPen device for purposes of Medicaid rebates.
Three federal agencies have remained mum about the settlement—announced on the eve of a federal holiday and during the media blitz over Donald Trump’s lewd remarks about women—because it has not been finalized. Mylan, and not the government, broke the news about its deal.
